Fagron Compounding Services recalled 34,260 bags of Vancomycin HCI Injection across the United States. The recall cites lack of sterility assurance and a blue Break-Off-Part that could detach from the administration port. Healthcare providers and patients should stop using the product immediately and follow manufacturer guidance.
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Consumers and healthcare providers should stop using this product immediately. Contact Fagron Compounding Services or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Vancomycin HCI is an antibiotic administered intravenously. This recall involves a compounded sterile product prepared by Fagron Compounding Services for distribution nationwide.
A blue Break-Off-Part could detach from the administration port, potentially compromising sterile integrity and allowing contamination.
This recall is not described as part of a broader industry pattern in the provided data.
High risk for sterile administration products used in clinical settings; delays or substitutions may affect patient care.
FDA enforcement report D-0440-2026 and recall notification letters
Refunds/replacements coordinated by Fagron with healthcare facilities; timelines may vary by institution
Keep all recall notices, lot numbers, expiration dates, and correspondence with supplier
Brand: Fagron Compounding Services. Product: Vancomycin HCI, 1.25 g added to 250 mL, 0.9% Sodium Chloride Injection USP. NDC: 71266-5083-01. Quantity: 34,260 bags. Distribution: Nationwide in the USA. Lot numbers and expirations listed in the notice.
No specific injuries or incidents are documented in the provided recall notice.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Fagron Compounding Services is recalling 11,680 bags of Vancomycin HCl 1 g in 250 mL 0.9% Sodium Chloride Injection. The recall is nationwide in the United States. The blue break-off part could detach from the administration port, raising sterility concerns. Stop using immediately and contact the provider for guidance.
Fagron Compounding Services recalled 5,140 bags of norepinephrine Bitartrate injection due to lack of sterility assurance. A blue Break-Off-Part could detach from the administration port. The recall covers nationwide distribution in the U.S. Consumers should stop use and contact providers for guidance.
Fagron Compounding Services recalled 2,980 syringes of a topical ophthalmic solution on November 20, 2025. The recall stems from an incorrect product formulation that could pose health risks. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
Fagron Compounding Services recalls 109,320 sterile single-dose bevacizumab syringes nationwide due to lack of assurance of sterility. Healthcare providers and patients should stop using the product immediately. Contact Fagron Compounding Services or a healthcare provider for guidance. The recall was issued on 2025-08-29 and remains active as of 2025-09-24.